SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...
The proposed Medicare coverage change could help Edwards Lifesciences gain market share from Medtronic and Boston Scientific, ...
One-year outcomes in the ENCIRCLE trial’s main cohort (299 patients unsuitable for other treatment options) achieved low rates for death and low heart failure hospitalization for patients treated with ...
Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...
Last month, Edwards Lifesciences recalled its SAPIEN 3 Ultra Delivery System after reports of burst balloons during implantation, resulting in significant difficulty retrieving the valve into the ...
EVOQUE tricuspid valve registry demonstrates more favorable outcomes than pivotal trial SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced data demonstrating successful patient ...
Edwards Lifesciences EW appears well-positioned to continue benefiting from the expanding adoption of its premium surgical ...
2026年第一季度营收达到16.5亿美元(同比增长12.7%),超出16亿美元的预期;调整后每股收益(EPS)为0.78美元,超出0.73美元的预测6.85%。 TAVR和TMTT产品线的强劲表现推动了业绩增长,调整后毛利率达78.2%,现金储备为24亿美元。 2026财年全年销售额增长指引从8%-10%上调至9%-11%;调整后每股收益(EPS)指引上调至2.95美元至3.05美元区间。 首席执 ...
Edwards Lifesciences had a monumental Q4 and full year 2025, growing sales 13.3% to $1.57 billion in the last quarter of the year. The company’s TAVR and TMTT performance are largely being credited ...
“Building on a year in 2025 marked by solid financial performance and strategic progress, we delivered another strong quarter in Q1, achieving 12.7% sales growth, which reflects the impact and ...